Suchergebnisse - "LABOTKA RICHARD"

PubPharm (98)

1

CD38-BINDING FUSION PROTEIN COMBINATION THERAPY

enthalten in: Europäisches Patentamt | 2024

von COLLINS SABRINA | PAROT XAVIER | LI SHUANG | +6

2

CD38-BINDING FUSION PROTEIN COMBINATION THERAPY

enthalten in: Europäisches Patentamt | 2024

von POGUE SARAH | COLLINS SABRINA | PAROT XAVIER | +8

3

Adjusting for subsequent therapies in the TOURMALINE-MM1 study shows clinically meaningful improvement in overall survival with addition of ixazomib to lenalidomide and dexamethasone

enthalten in: Haematologica | 2024

von Ramasamy, K. | Bahlis, N. | Kumar, S. | +7

4

Late versus early response and depth of response are associated with improved outcomes in patients with newly diagnosed multiple myeloma enrolled in the TOURMALINE-MM2 trial

enthalten in: EJHaem | 2023

von Richardson, P. | Facon, T. | Venner, C. | +18

5

Dose Titration of Ixazomib Maintenance Therapy in Transplant-Ineligible Multiple Myeloma : Exposure-Response Analysis of the TOURMALINE-MM4 Study

enthalten in: Clinical pharmacology and therapeutics | 2023

von Srimani, J. | Diderichsen, P. | Hanley, M. | +2

6

Ixazomib Versus Placebo as Postinduction Maintenance Therapy in Newly Diagnosed Multiple Myeloma Patients : An Analysis by Age and Frailty Status of the TOURMALINE-MM4 Study

enthalten in: Clinical lymphoma, myeloma & leukemia | 2023

von Bringhen, S. | Pour, L. | Benjamin, R. | +11

7

COMBINATION THERAPY FOR CANCER TREATMENT

enthalten in: Europäisches Patentamt | 2023

von LABOTKA RICHARD | FERGUS ANDREW

8

Quality of life and symptoms among patients with relapsed/refractory AL amyloidosis treated with ixazomib-dexamethasone versus physician's choice

enthalten in: American journal of hematology | 2023

von Sanchorawala, V. | Wechalekar, A. | Kim, K. | +13

9

MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials

enthalten in: Blood | 2023

von Paiva, B. | Manrique, I. | Dimopoulos, M. | +17

CommentIn: Blood. 2023 Feb 9;141(6):557-558. - PMID 36757729

10

A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therapy for multiple myeloma

enthalten in: Blood cancer journal | 2023

von Chng, W. | Lonial, S. | Morgan, G. | +12

1
2
3
4
5
6
7
8
9
10
Nächster »
[10]